- Day 1 - Tuesday, September 26th
- Day 2 - Wednesday, September 27th
- Day 3 - Thursday, September 28th
Registration & Networking
Chairs Opening Remarks and Setting the Scene
Seth Feuerstein, Founder & CEO, Oui Therapeutics
Keynote Panel Discussion: DTx Today: Are We Where We Thought We Would Be?
- Has 2023 panned out differently to how you envisioned it to?
- What’s gone right? Can each speaker give one aspect of the industry which is prospering?
- Now, what’s gone wrong? Can each speaker give one aspect of the industry which is struggling?
- Which stakeholders need to take charge and help to implement change?
Moderator: Andy Molnar, Chief Executive Officer, Digital Therapeutics Alliance
Michael Hasselberg, Chief Digital Health Officer, University of Rochester Medical Center
Omar Manejwala, Chief Medical Officer, Dario Health
Ramita Tandon, Chief Clinical Trials Officer, Walgreens
Liesl Oldstone, Vice President, Health Economics & Market Access, AppliedVR
Keynote Panel Discussion: Details Matter: Best Practices for Evidence Assessment in Digital Health
- How should evidence be used to inform adoption decisions for digital health interventions?
- How can digital health solutions providers generate appropriate evidence in an efficient and feasible manner?
- What evidence quality criteria may be important when assessing the potential health equity impact of digital health interventions? Beyond encouraging representativeness, what are best practices to investigate (at least) noninferiority in underserved patient groups?
- What are some key quality criteria for assessment of real-world evidence in digital health? When is this term appropriate—and when can it be misleading?
- What are some of the highest priority steps we can take in the digital health community to move in an evidence-based direction and improve clinical outcomes across diverse groups of patients?
Moderator: Jordan Silberman, Director of Clinical Analytics and Research, Digital Care Delivery, Elevance Health
Siavash Sarlati, Medical Director, Elevance Health
Jennifer Goldsack, Chief Executive Officer, Digital Medicine Society
Anindita Saha, Assistant Director, Digital Health Center of Excellence, FDA
Andrey Ostrovsky, Former Chief Medical Officer, US Medicaid Program
Morning Refreshments & Networking
DTx East will now split into two tracks. Attendees are welcome to attend either Track 1 or Track 2 and swap between them during the course of the day.
Chaired by Seth Feuerstein, Founder & CEO, Oui Therapeutics
11:40am EST
Presentation: Large Scale Global Digital Assessments
- How do we ‘localize’ Digital Biomarkers to different regions?
- How do we make measurements across languages and cultures?
- How do we achieve scale?
Vaibhav Narayan, Executive Vice President, David Alzheimers Collaborative
12:05pm EST
Panel Discussion: Diversifying the DTx Portfolio
- Having one end solution doesn’t cut it, it’s time to get creative
- How would you define the current climate of digital therapeutics?
- Are we seeing an urgency for companies to branch out from solely DTx solutions?
- Which stakeholders should companies be looking to partner up with?
- How do companies need to be thinking to survive in the DTx industry?
Patricia Bradley, Global Chief Commercial Officer, MindMaze
Ciara Clancy, Chief Executive Officer, Beats Medical
Kal Patel, Co-Founder & CEO, BrightInsight
Josh Gaffey, VP Digital Health & Medicine, Head of Strategy, Pipeline & Engineering, Pfizer
Quynh Pham, Scientific Investigator & Principal Investigator, Centre for Digital Therapeutics, University Health Network
Chaired by Amir Lahav, Strategic Advisor, Pharma & MedTech
11:40am EST
Presentation: Truly Defining Digital Therapeutics
- What is a digital therapeutic?
- What is the difference between a digital therapeutic and a prescription digital therapeutic (PDT)?
- Where do digital therapeutics sit within Digital Health?
- What variations of DTx exist?
Kim Baden-Kristensen, Founder & CEO, Brain+
12:05pm EST
Panel Discussion: The Key Components of Building a Successful DTx Product
- What are the elements you must take into account when building a DTx product?
- Has the criteria changed over the past few years?
- How to design a DTx product?
- What are the major stakeholders looking to see in a digital therapeutic: Policy makers, HCPS and Payers?
- How should you be thinking about the patient when building your digital therapeutic?
Moderator: Mette Dhyrberg, Founder & CEO, Mymee
Mark Guarraia, VP, Design & User Experience, Novo Nordisk
Owen McCarthy, President, Board of Directors, & Co-Founder, MedRhythms
Kristin Wynholds, Chief Product Officer, Better Therapeutics
Tim Campellone, VP, Translational Science, Woebot Health
Lunch & Networking
2:30pm EST
Fireside Chat: Good Data Stewardship Benefits us All: How to Protect Every Stakeholder in Healthcare
- What does good data stewardship entail, and why is it important?
- What role do DTx platforms play in facilitating the movement of data in the healthcare ecosystem? How do we plan for data reuse and outline permissions for new use cases with existing data, especially as more data streams become available?
- Which security measures, certifications, and data harmonization practices should DTx platforms obtain or perform to protect every stakeholder in healthcare? What are the regulatory compliance implications of emerging requirements such as FDA 21CFR Part 11?
- How should pharma, health systems, and payers engage with DTx platforms to ensure good data stewardship and maintain patient trust?
Yury Rozenman, SVP of Pharmaceutical & Life Sciences, Propeller Health
Susa Monacelli, General Manager, Propeller Health
2:55pm EST
Panel Discussion: Bringing Digital into Women’s Health: The Future of Femtech
- How can digital tools be best utilized to reimagine women’s health?
- Which companies are doing interesting work in the space? What can they teach us?
- How can DTx be incorporated to make Femtech more accessible?
- What are the current challenges in providing accessible and high quality perinatal care?
- Where are we seeing gaps in provider understanding & education of women’s health journet and how can we strategize to tackle these?
Missy Lavender, Chief Executive Officer, Renalis
Elina Berglund, Chief Executive Officer Natural Cycles
Colette Courtion, Chief Executive Officer, Joylux
Eileen Maus, Chief Executive Officer, Axena Health
2:30pm EST
Presentation: Laying Out the Roadmap for Achieving Commercial Success in Digital Therapeutics
- What are your options for achieving commercial success?
- What does DTx bring to the table that other medical solutions are missing?
- How to build a well polished digital therapeutics commercial business model?
Joe Perekupka, Chief Executive Officer, Freespira
2:55pm EST
Panel Discussion: What I Didn’t Know That I Do Know Now…
- Lessons learnt from the DTx veterans
- Tips and tricks for starting a digital therapeutics company
- What should companies avoid when entering the market?
- How to make your business model attractive to investors?
- What are some key trends and advancements to watch for in the DTx space over the next few years?
Anand Iyer, Chief Analytics Officer, Welldoc
Matthias Zenker, Chief Medical Solutions Officer, GAIA AG
Scott Kollins, Chief Medical Officer, Akili Interactive
Afternoon Refreshments & Networking
Panel Discussion: Breaking Down the Wall of Provider & Patient Adoption of DTx: What’s Still Stopping Us?
- What are the key areas we need to address to help increase adoption of digital health tools?
- How do we better educate physicians and patients that DTx can solve unmet medical needs? Is evidence lacking?
- What changes need to be made within the clinician workflow to give HCPs better access to digital therapeutics?
- Are people ready for DTx? What’s it going to take? Are we stuck?
Moderator: Diane Gomez-Thinnes, Chief Commercial Officer, Better Therapeutics
Elli Kaplan, Co-Founder & Chief Executive Officer, Neurotrack
Benjamin Alouf, Chief Medical Officer, Limbix
JD Friedland, Managing Director, Ventures, Cleveland Clinic
Peter Clardy, Senior Clinical Specialist, Google
Chairs Closing Remarks
Seth Feuerstein, Founder & CEO, Oui Therapeutics
DTx East Drinks Reception
End of DTx East Day 1
Registration & Networking
Chairs Opening Remarks and Setting the Scene
Frank Karbe, Chief Executive Officer, Better Therapeutics
Keynote Presentation: A Mutually Beneficial Partnership Between DTx and Employers: How Did We Do It?
- Insights into establishing a partnership with a large employer group
- How can DTx companies make themselves more attractive to employers?
- Are we going to see more of these partnerships moving forward?
Chris Wasden, Chief Strategy Officer, Twill
Keynote Panel Discussion: Painting the Picture of the Future of Digital Therapeutic Partnerships
- Who will DTx be looking to partner with going into 2024?
- What role is pharma going to continue to play in digital therapeutics?
- What options do digital therapeutic companies have when it comes to partnering?
- What are your options? How do you ensure you’re making the right decision between Pharma, Employers, HCPs, etc.?
Moderator: Anish Shindore, Managing Partner, GSD Health
Santosh Shahnbhag, Chief Financial Officer, Akili Interactive
Sam Oddsson, Co-Founder & Chief Clinical Officer, Sidekick Health
Amy McDonough, Managing Director & GM, Fitbit Health Solutions, Google
Morning Refreshments & Networking
Chaired by Frank Karbe, Chief Executive Officer, Better Therapeutics
11:20am EST
Presentation: Current Reimbursement Landscape and Adoption Hurdles in Japan
- Current regulatory and reimbursement landscapes and upcoming policies
- Real-world data from CureApp’s hypertension PDT
- Adoption hurdles in the market and our approach to physician engagement
Yosuke Shimizu, Lead, Global Business Development, CureApp
11:45am EST
Beyond the Download: Exploring Techniques for Long-Term Patient Engagement in Digital Therapeutics
- What strategies are DTx companies implementing to increase long-term retention of their products?
- Where are we seeing the most success in patient engagement e.g. Utilizing a payer, employer or direct to consumer?
- How can digital be utilized to better the patient journey?
Moderator: Cecile Dubois, Co-Founder & CEO, Sonio
Neil Hattangadi, Chief Executive Officer, Cortica
Vijay Ravindran, Chief Executive Officer, Floreo
Craig Lund, Chief Executive Officer, Mightier
Jessica McKinney, VP Medical Affairs & Clinical Advocacy, Axena Health
Chaired by Ana Maiques Karbe, Chief Executive Officer, Neuroelectrics
11:20am EST
Case Study: Designing Clinical Trials for Digital Therapeutics: Best Practices and Lessons Learned
- Real-world case studies highlighting the importance of reaching, recruiting, and, most importantly, retaining a diverse target population longitudinally to generate robust real-world evidence.
- Overview of the Intuition Study and the early learnings showing the feasibility of understanding real-world cognitive outcomes
Abhishek Pratap, Head of Data Innovation, Biogen
Richard Hughes, Head of Cognitive & Mental Health Sciences, Biogen
11:45am EST
Panel Discussion: Challenges and Solutions in Conducting Clinical Trials for Digital Therapeutics
- Are digital biomarkers and wearables going to streamline clinical trials to make them more efficient?
- What seems to be getting in the way of adopting decentralized clinical trials? What are we waiting for?
- Are we taking enough consideration to ensure that socio-economic, gender and racial diversity is the data?
- What does the future of DTx clinical trials look like?
- What advice would you give to start-ups when running their first DTx clinical trial?
Moderator: Danielle Bradley, Senior Director of Clinical Value & Evidence, Big Health
Tim Callahan, VP, Scientific Affairs, Philips Pharma Solutions
Robert Gabbay, Associate Professor of Medicine, Harvard Medical School
Josh Rose, VP, Head of Clinical Trial Delivery, Site Solutions Strategy, CVS Health
Elena Heber, Co-Founder & Chief Clinical Officer, HelloBetter
Lunch & Networking
2:10pm EST
Presentation: 5 Ruinous Blunders Companies Make When Presenting to Payers and How to Fix Them
- Getting to Grips with Digital Therapeutic Reimbursement and Public Policy Opportunities
- An update on the current DTx reimbursement landscape, how is this changing?
- Which business models are more attractive to payers?
- What are the legislative options for reimbursing digital therapeutics?
Matthew Tucker, Chief Commercial Officer, Nightware
2:35pm EST
Fireside Chat: Understanding the Fundamental Differences Between Scaling DTx in the US vs Europe
- What are the different challenges we’re facing in market entry and how to mitigate them?
- How to manage varying legislation requirements?
- How to ensure you have a plan for scaling when awaiting reimbursement?
- What changes can we see in the landscape in the EU and in the US?
- How to manage the changing trends in DTx, including hybrid models and app fatigue?
- What is the next wave for DTx?
Emanuela Kufel, Co-Founder & UK CEO, Prosoma
Andrzej Jonczyk, Co–Founder, Chief Strategy Officer & Head of USA, Prosoma
2:10pm EST
Presentation: How the VA Plan to Integrate Digital Into Their Workflow
- How can digital be incorporated into healthcare to deliver more appropriate care models?
- What is the VA looking for when assessing digital therapeutic tools?
- What are your options when building your payment model?
Cole Zanetti, Chief Health Informatics Officer | Senior Advisor for the VA Center for Care & Payment Innovation, U.S Department of Veterans Affairs
2:35pm EST
Panel Discussion: Managing the Regulatory Obstacles for SaMDs in 2023
- There is an unwritten dichotomy between what software based DTx are & how the regulatory frameworks are organized
- How much of an algorithm can you change for its regulatory classification to change?
- How are companies managing to innovate software with regulatory barriers in the way?
- What needs to change in the framework?
- How do we implement the change?
- Patient outcomes how should FDA consider the regulatory aspects and the patient aspects what is the evidence and outcomes focus
Jyotsna Mehta, Founder & CEO, Keva Health
Carrie Nixon, Managing Partner, Nixon Gwilt Law
Smit Patel, Associate Director, Digital Medicine Society
Afternoon Refreshments & Networking
Panel Discussion: Rethinking the Rules on Digital Therapeutics Commercial Strategy
- What commercial models exist outside of the PDTs route?
- How may certain product profiles suit some commercial models better than others?
- Where should DTx companies be looking for partners to help scale-up business?
- How could DTx companies collaborate better?
- What can DTx learn from telehealth, digital health and virtual first care?
- What’s the missing piece to scaling DTx?
Moderator: Matthew Tucker, Chief Commercial Officer, Nightware
Danny Kim, Head of WELT USA, WELT
Abhishek Shah, Co-Founder & CEO, Wellthy Therapeutics
Shefali Shah, Global VP, Market Value & Commercial Effectiveness, MindMaze
David Klein, Co-Founder & CEO, Click Therapeutics
Chairs Closing Remarks
Frank Karbe, Chief Executive Officer, Better Therapeutics
End of DTx East Day 2
Registration & Networking
Chairs Opening Remarks & Setting the Scene
Risa Weisberg, Chief Clinical Officer, BehaVR
Shark Tank Pitches – DTx Start-Up Companies Pitch to A Panel of Investors
Start-Up DTx Companies
Companies to be Announced
Investors
Linda Li, Partner, Cleveland Clinic Ventures
Alexandra Lundin, Vice President, Insight Partners
Alyssa Reisner, Director & Principal, CVS Ventures
Adam Kundzewicz, Executive Director, Venture Fund, Boehringer Ingelheim
Morning Refreshments & Networking
Closing Panel: Lessons Learnt from a Decade in DTx: How to Stay Thriving
- A deep dive into how you shouldn’t build a digital therapeutics business
- Industry pioneers discuss learnings after 10 years of barrier breaking, successes, false starts, and pivots
- What are some emerging trends in the industry that may affect the success of digital therapeutics companies?
- What could Pear Therapeutics have done differently looking back?
- Where are the warning signs that a digital therapeutics company may be in trouble?
- Going forward, how can others learn from these failures to avoid making similar mistakes?
Eddie Martucci, Chief Executive Officer, Akili Interactive
Andy Molnar, Chief Executive Officer, Digital Therapeutics Alliance
Edward Cox, Head & General Manager of Digital Health, Pfizer
Chairs Closing Remarks
Risa Weisberg, Chief Clinical Officer, BehaVR